DealBio
All collections

Investor Intelligence

11 Cancer Immunotherapy Investors in Europe

European investors with demonstrated activity across T-cell engagers, T-cell receptor medicines, immune-oncology antibodies and other platforms designed to mobilise the immune system against cancer.

Published
  • Cancer Immunotherapy
  • Oncology
  • Cell Therapy
  • Antibody Therapeutics
  • Europe
  • Series A

financing in Europe is broadening beyond established checkpoint inhibitors. Recent rounds include , , and programmable cell therapies, with capital coming from specialist VCs, research-linked funds and public investment organisations. That diversity matters because these programmes combine difficult biology with long clinical-development timelines and substantial financing needs.

DealBio selected 11 investors with evidenced relevance to cancer immunotherapy in Europe, using current investor research, financing precedents and public verification where needed.

Abingworth

Life-sciences venture investor backing therapeutics from company creation through clinical development.

Stage
Seed · Series A · Growth
Sector / Focus
Cancer immunotherapy · Biotech · Therapeutics
Investment markets
United Kingdom · Europe · United States
Investor type
VC

Relevant investment

Abingworth supported Cytospire Therapeutics as an existing investor in its £61 million ($83 million) Series A in May 2026. Cytospire is developing multispecific gamma-delta T-cell engager antibodies designed to direct the immune system against solid and liquid tumours.

Cambridge Innovation Capital

Cambridge-focused venture investor backing deep-tech and life-sciences companies emerging from the regional research ecosystem.

Stage
Seed · Series A
Sector / Focus
T-cell therapies · Cancer immunotherapy · Life sciences
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

Cambridge Innovation Capital co-led T-Therapeutics’ £48 million ($59 million) Series A in 2023. The University of Cambridge spinout is developing fully human T-cell receptor medicines intended to redirect T cells against cancer targets.

Criteria Bio Ventures

European life-sciences venture firm investing in therapeutic biotechnology companies.

Stage
Seed · Series A
Sector / Focus
Cancer immunotherapy · Oncology · Biotech
Investment markets
Europe
Investor type
VC

Relevant investment

Criteria Bio Ventures backed Adaptam Therapeutics’ €3 million financing in 2025. Adaptam is developing cancer immunotherapies aimed at immunosuppressive in the , providing a highly specific immuno-oncology precedent.

LifeArc Ventures

Investment arm of the UK medical-research charity LifeArc, backing companies translating biomedical science into new treatments.

Stage
Seed · Series A · Series B
Sector / Focus
Immunology · Cancer immunotherapy · Therapeutics
Investment markets
United Kingdom · Europe
Investor type
VC / Research-backed investor

Relevant investment

LifeArc Ventures supported Cytospire Therapeutics in its £61 million ($83 million) Series A in 2026. Cytospire’s multispecific antibodies are designed to recruit gamma-delta T cells against cancers, linking LifeArc directly to a differentiated immune-cell engager platform.

Oncode Oncology Bridge Fund

Early-stage oncology fund translating research from Oncode Institute into investable cancer companies.

Stage
Pre-seed · Seed
Sector / Focus
Immuno-oncology · Oncology therapeutics · Translational research
Investment markets
The Netherlands · Europe
Investor type
Research-linked venture fund

Relevant investment

Oncode Oncology Bridge Fund provided early financing to Immagene, now Flindr Therapeutics, whose founding work included next-generation precision immuno-oncology. The company later raised €20 million in 2024 to advance first-in-class cancer therapies, illustrating the fund’s role in bridging academic oncology research into venture-backed development.

Medicxi

European life-sciences investment firm focused on drug-development companies and asset-centric biotechnology.

Stage
Seed · Series A · Growth
Sector / Focus
Oncology · Antibody therapeutics · Cancer immunotherapy
Investment markets
Europe · United States
Investor type
VC

Relevant investment

Medicxi was the founding investor in Ottimo Pharma and participated in its Series A of more than $140 million in December 2024. Ottimo is developing Jankistomig, a / bifunctional antibody designed to combine immune-checkpoint blockade with inhibition of tumour angiogenesis.

RTW Investments

Life-sciences investment firm spanning private and public biotechnology companies.

Stage
Series A · Growth
Sector / Focus
Cancer immunotherapy · Antibody therapeutics · Oncology
Investment markets
United Kingdom · United States · Europe
Investor type
Investment firm

Relevant investment

RTW Investments participated in Ottimo Pharma’s Series A of more than $140 million in 2024. Ottimo’s lead PD-1/VEGFR2 bifunctional antibody is designed to activate anti-tumour immunity while disrupting blood-vessel signalling that supports tumour growth.

Pathway Bioventures

Specialist life-sciences venture investor backing biotechnology companies from early clinical development onward.

Stage
Series A
Sector / Focus
Cancer immunotherapy · Oncology · Biotech
Investment markets
United Kingdom · Europe
Investor type
VC

Relevant investment

Pathway Bioventures joined Cytospire Therapeutics’ £61 million ($83 million) Series A in May 2026. The financing is advancing first-in-class gamma-delta T-cell engager antibodies toward clinical testing in solid and liquid tumours.

British Business Bank

UK government-owned development bank investing directly and through funds to support growth and innovation.

Stage
Seed · Series A · Growth
Sector / Focus
Life sciences · Cancer immunotherapy · UK growth capital
Investment markets
United Kingdom
Investor type
Public investment organisation

Relevant investment

British Business Bank invested £12 million directly in Cytospire Therapeutics as part of the company’s £61 million ($83 million) Series A in 2026. The financing will advance Cytospire’s gamma-delta T-cell engager pipeline toward studies in cancers including EGFR-positive solid tumours.

Calculus Capital

UK growth investor backing healthcare, technology and other knowledge-intensive businesses.

Stage
Seed · Series A · Growth
Sector / Focus
Cancer therapeutics · Gene and cell therapy · Biotech
Investment markets
United Kingdom
Investor type
VC

Relevant investment

Calculus Capital participated in Trogenix’s £70 million ($95 million) Series A in October 2025. Trogenix is developing precision cancer therapies that use synthetic gene-control programmes to expose and kill aggressive tumour cells, including a lead programme for .

Eos Advisory

Scottish investment firm backing early-stage science, technology and healthcare businesses.

Stage
Seed · Series A
Sector / Focus
Cell therapy · Gene control · Cancer immunotherapy
Investment markets
United Kingdom
Investor type
VC

Relevant investment

Eos Advisory participated in the expansion of Laverock Therapeutics’ seed financing, which brought total capital raised to more than £20 million in 2025. Laverock is developing programmable gene-control technologies for T-cell and macrophage therapies, with oncology programmes showing enhanced tumour control in preclinical models.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.